Shopping Cart
Remove All
Your shopping cart is currently empty
Tifcemalimab (JS004) is a humanised antibody targeting BTLA (B and T lymphocyte attenuator), which binds to BTLA and blocks the interaction between HVEM and BTLA, exhibiting immunomodulatory and antitumour activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | In Stock | In Stock | |
| 5 mg | $645 | In Stock | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,460 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock |
| Description | Tifcemalimab (JS004) is a humanised antibody targeting BTLA (B and T lymphocyte attenuator), which binds to BTLA and blocks the interaction between HVEM and BTLA, exhibiting immunomodulatory and antitumour activity. |
| Synonyms | JS004, Icatolimab |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CD272/BTLA |
| Molecular Weight | 145.98 kDa |
| Cas No. | 2236068-83-8 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG4 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.